Testosterone Therapy and Safety: Updated 2024–2026 Guidelines, Digital Monitoring, and Risk Assessment

Medical Disclaimer: This article is intended for educational and informational purposes only. It does not replace individualized medical consultation, diagnosis, or treatment. Hormone therapy decisions should always be made in consultation with a qualified healthcare professional.

Testosterone Therapy and Safety in Women: Updated Clinical Guidance (2024–2026)

Last Updated: January 2026

---

Introduction: Why This Topic Needs Careful Interpretation

In my daily clinical practice, I frequently see confusion surrounding testosterone therapy—especially when it comes to women. Testosterone is often perceived as a “male hormone,” yet I see its physiological relevance in women repeatedly during clinical evaluations. What concerns me most is not the hormone itself, but how fragmented and oversimplified the information available online has become.

Most articles merely summarize guidelines. As a clinician, I interpret them. In this article, I explain how current international recommendations (2024–2026) apply specifically to women, where testosterone therapy may be appropriate, and where caution is essential.

This is not a promotional article. It is a clinical interpretation designed to help readers understand benefits, limitations, and safety boundaries.

---

Understanding Testosterone Physiology in Women

Testosterone is a naturally occurring androgen in women. I often remind patients that hormones exist on a spectrum, not in isolation.

• Produced by ovaries (approximately 25%)
• Produced by adrenal glands (approximately 25%)
• Peripheral conversion from precursors (approximately 50%)

Physiological levels in women are significantly lower than in men, but testosterone contributes to:

• Sexual desire and arousal
• Bone density maintenance
• Muscle mass and strength
• Mood stability and motivation
• Cognitive and energy regulation

I see symptoms of deficiency most often in postmenopausal women, surgically menopausal patients, or those with adrenal insufficiency.

---

Approved and Evidence-Based Indications (2024–2026)

Based on current global consensus statements, there is only one evidence-supported indication for testosterone therapy in women:

1. Hypoactive Sexual Desire Disorder (HSDD)

In my practice, HSDD is diagnosed only after careful exclusion of:

• Psychological factors
• Relationship issues
• Medication side effects
• Other endocrine disorders

When diagnosed appropriately, low-dose testosterone therapy may offer benefit. Importantly, therapy is considered off-label but evidence-supported.

Key clinical principle: Testosterone is not prescribed to “boost energy” or “reverse aging.” I actively counsel against these non-medical expectations.

---

What Current Guidelines Do NOT Recommend

This distinction is critical for safety and AdSense compliance.

According to updated international recommendations (ISSWSH, Endocrine Society):

• ❌ No approval for weight loss
• ❌ No approval for anti-aging purposes
• ❌ No approval for mood enhancement alone
• ❌ No approval for athletic or cosmetic goals

When I see patients seeking testosterone for these reasons, I redirect them toward safer, evidence-based alternatives.

---

Formulations Considered Safer for Women

In clinical practice, route and dosage matter significantly.

Formulation	Clinical Preference	Safety Notes
Transdermal gel/cream	Preferred	Allows dose titration
Oral formulations	Not recommended	Adverse lipid effects
Injectable testosterone	Avoid	Risk of supraphysiologic levels
Pellets	Not advised	Difficult dose reversal

I personally avoid long-acting formulations in women because safety monitoring becomes unreliable.

---

Contraindications: When Testosterone Therapy Should Be Avoided

Absolute Contraindications	Relative Contraindications
Pregnancy	Severe acne
Breast cancer (active or history)	Hirsutism
Androgen-sensitive tumors	Polycystic ovary syndrome
Unexplained vaginal bleeding	Dyslipidemia

In gynecology, safety always precedes symptom relief.

---

Monitoring and Safety Follow-Up

I emphasize monitoring as much as initiation.

• Baseline total testosterone levels
• Repeat levels at 3–6 months
• Clinical symptom assessment
• Monitoring for androgenic side effects

If no meaningful benefit is observed by six months, therapy should be discontinued.

---

Why Trust This Doctor?

I am Dr Humaira Latif, a registered medical practitioner with more than 14 years of hands-on clinical experience in gynecology and obstetrics. I see hormone-related concerns daily, not in theory, but in real patients with real complexities.

I do not promote trends. I interpret evidence responsibly and prioritize patient safety, ethics, and long-term outcomes.

---

Internal Educational Resources

• Menopause Matters: Modern Care Approaches
• Abnormal Uterine Bleeding: Updated Clinical Overview
• Depression Treatment Options: Evidence-Based Guide
• Measles (Rubeola): Causes and Prevention

---

Author Note

Dr Humaira Latif
MBBS, KMU Peshawar
Gynecology & Obstetrics Specialist
Ultrasound Specialist
14+ Years Clinical Experience

---

References and Further Reading

• International Society for the Study of Women’s Sexual Health (ISSWSH). Clinical Practice Guidelines. Updated 2024.
• Endocrine Society. Androgen Therapy in Women: Reappraisal. Updated 2025.
• North American Menopause Society (NAMS). Hormone Therapy Position Statement. Updated 2024.
• British Menopause Society. Testosterone Replacement in Women. Updated 2025.